At the interface of antioxidant signalling and cellular function: Key polyphenol effects

Asimina Kerimi and Gary Williamson

School of Food Science and Nutrition, University of Leeds, Leeds, UK

The hypothesis that dietary (poly)phenols promote well-being by improving chronic disease-risk biomarkers, such as endothelial dysfunction, chronic inflammation and plasma uric acid, is the subject of intense current research, involving human interventions studies, animal models and in vitro mechanistic work. The original claim that benefits were due to the direct antioxidant properties of (poly)phenols has been mostly superseded by detailed mechanistic studies on specific molecular targets. Nevertheless, many proposed mechanisms in vivo and in vitro are due to modulation of oxidative processes, often involving binding to specific proteins and effects on cell signalling. We review the molecular mechanisms for 3 actions of (poly)phenols on oxidative processes where there is evidence in vivo from human intervention or animal studies. (1) Effects of (poly)phenols on pathways of chronic inflammation leading to prevention of some of the damaging effects associated with the metabolic syndrome. (2) Interaction of (poly)phenols with endothelial cells and smooth muscle cells, leading to effects on blood pressure and endothelial dysfunction, and consequent reduction in cardiovascular disease risk. (3) The inhibition of xanthine oxidoreductase leading to modulation of intracellular superoxide and plasma uric acid, a risk factor for developing type 2 diabetes.

Keywords:
Endothelial function / Flavonoid / Inflammation / Phenolic acid / Uric acid

1 Introduction

The increasing occurrence of nutrition-related diseases collectively clustered under the term metabolic syndrome, and the spiralling cost of clinical treatment, has resulted in heightened interest in plant bioactives and their postulated protective role as part of a healthy diet. For many years, the chemical action of polyphenols, flavonoids, “tannins” and phenolic acids (referred to here collectively as (poly)phenols) as antioxidants was considered to be the primary mechanism of action in vivo to explain epidemiological and intervention studies, animal studies, and popular interpretations such as the “French paradox” or the “Mediterranean diet” [1]. Chemical antioxidant activity can be readily measured in vitro, but, in the last few years, it has become clear that the effects of (poly)phenols in vivo are due to much more complex modes of action [2], with multiple but modest effects on different targets, adding up to a substantial overall response. These pleiotropic effects reported in the literature point to numerous potential targets of (poly)phenols derived mainly from cell studies and animal models, but only some of these are backed up by human intervention studies. Although the direct action of (poly)phenols in vivo as purely chemical antioxidants is mostly discredited, many of the proposed mechanisms in vivo are related to oxidative processes, involved in cell signalling, inflammation, insulin resistance, glucose and lipid metabolism, mitochondrial function and superoxide production. Data from recent studies suggests that the efficiency of dietary bioactives in modulating plasma biomarkers also depends on the health status of individuals. In fact, in some cases the most positive results are obtained in people already...
with some increased risk factors for cardiometabolic disease. Healthy subjects with low levels of oxidative stress showed a reduced responsiveness to nutritional interventions [3]. Here, we consider how the “antioxidant hypothesis” is now maturing, allowing relevant mechanisms of action to be discovered in vitro and then confirmed in vivo, and also for efficacy data from in vivo intervention studies to be explained mechanistically from in vitro data. To address these issues, we have taken several examples where human intervention data have provided evidence of real effects, and where there is mechanistic data from in vitro or animal models to support the data.

After oral consumption, there are several possible pathways of absorption and metabolism of (poly)phenols depending on the chemical structure and nature of attached moieties. These have been reviewed extensively elsewhere and are quite well understood [4, 5]. After consumption of phenolic acids such as chlorogenic acid in coffee, the resulting predominant compounds in the blood are ferulic acid-O-sulfate, dihydroferulic acid-O-sulfate, dihydroferulic acid and dimethoxycinamic acid, along with numerous other less abundant compounds [6, 7]. Following consumption of quercetin or (−)-epicatechin, O-sulfated, O-glucuronidated and O-methylated forms appear in plasma fairly rapidly, followed by various microbiota-derived phenolic compounds and their conjugates at later times [8, 9]. It should be noted that flavonols contain stereochemical centres giving rise to different enantiomeric forms, denoted as (+) and (−). The naturally occurring form of epicatechin is (−)-epicatechin (and derivatives) and of catechin is (−)-catechin, and these are indicated when it is clear which form was used. However, some processing and extraction techniques can cause formation of (−)-epicatechin and of (−)-catechin [10], which are not resolved on a reverse phase HPLC column, and therefore not readily observed [11]. Therefore some of the effects ascribed to (epi)catechins in this report may be due to enantiomeric mixtures, if not explicitly stated. This may be important since the enantiomers may have different bioavailabilities [12] and bioactivities [13]. Microbial metabolites, after consumption of berries rich in multiple (poly)phenols, reached high concentrations up to 20 μM in the blood [14]. Anthocyanins and procyanidins are poorly absorbed in their intact form, but microbial and chemical breakdown products are well absorbed and appear in plasma and urine [15, 16]. The extensively studied (poly)phenol resveratrol, on the other hand, is quickly absorbed but rapidly metabolised resulting in low bioavailability of the parent compound [17]. The complexity and diversity of compound structures poses a challenge when designing in vitro experiments, where cells are treated with relevant concentrations and chemical forms of (poly)phenols and metabolites compared to normal dietary consumption of (poly)phenols. Previously, we have recommended strategies for tackling this issue [18]. Treating with single compounds in vitro does not take into account the complex mixture of plasma metabolites that could have additive, antagonistic or even synergistic effects. An alternative approach is to first undertake intervention studies and determine an “effect,” i.e. a change in a relevant biomarker. Ideally the study should be conducted by using high (poly)phenol-containing food, supplements or pure (poly)phenols on a well-defined cohort, preferably monitoring some sub-optimal biomarkers. If an improvement in the chosen biomarker is observed in vivo, then the mechanism should be further studied in vitro. This approach helps to circumvent the arguments concerning which concentrations or forms to use in vitro, since the goal is not to extrapolate an in vivo effect directly from the in vitro studies. Nevertheless, the most relevant effects will be those occurring at the lowest concentrations of the bioactive (conjugate/metabolites), taking into account the pleiotropic effects to allow for multiple mechanisms of action. We have examined this alternative approach here for three examples, chronic inflammation, endothelial effects and plasma uric acid, where (poly)phenols have been shown to have an effect in vivo, and we consider the in vitro data as a way of substantiating the mechanism. This “nutritional” approach is different to that followed in drug design, where the first step is in vitro screening to identify active compounds, which are then ultimately taken to phase II and III trials in vivo. It should be noted that nutrition is fundamentally different to drug discovery in that we are already consuming (poly)phenols through the diet everyday as part of normal nutrition especially with a healthy lifestyle. This approach also takes into account interactions with nutrients and with the host, such as attenuating or blunting post-prandial sugar spikes or targets of microbial metabolites, which in a previous review we argue are very important when assessing the action of (poly)phenols in vivo [19].

2 Effects of (poly)phenols on chronic inflammation

Inflammation followed by infection or tissue injury constitutes a physiological response to harmful stimuli and is meant to aid towards re-establishment of homeostasis. The classical acute inflammatory response involves the delivery of plasma components and leucocytes to the site of insult and leads to the production of different types of inflammatory mediators grouped as chemokines, cytokines, vasoactive amines, eicosanoids and products of proteolytic cascades that can act as endothelial constriction agents [20]. However, the extent of the inflammatory activation characterising the preceding state of diabetes or subsequently the development of the metabolic syndrome is not as large, and hence is termed “low grade” or “low-intensity” chronic inflammation, evidenced by an increased concentration of circulating inflammatory mediators in an asymptomatic form [21].

Very few human studies have been reported where the effects of (poly)phenols on inflammation are the primary outcome. Several studies have reported effects on inflammatory markers, but only under certain conditions. In a randomized, double-blind, placebo-controlled crossover trial involving healthy (pre)hypertensive volunteers, (−)-epicatechin
(100 mg/d for 4 weeks) changed soluble endothelial selectin (sE-selectin) but the change in z score for endothelial dysfunction was only a trend. In the same study, quercetin-3-O-glucoside (160 mg/d for 4 weeks) changed sE-selectin and IL-1β, and reduced the z score for inflammation [22]. Quercetin aglycone (500 mg/day) given to women for 10 weeks decreased systolic, but not diastolic, blood pressure, but had no effect on IL-6, α-TNF and C-reactive protein compared to the placebo [23]. Acute ingestion of 1000 mg quercetin, 120 mg epigallocatechin 3-gallate, 400 mg quercetin-3-O-glucoside, 400 mg eicosapentaenoic acid, 400 mg docosahexaenoic acid, 1000 mg vitamin C and 40 mg niacinamide, 15 min before heavy exercise in endurance athletes, did not affect post-exercise inflammatory markers nor immune changes [24]. In community-dwelling adult females, quercetin, at 500 and 1000 mg/day for 12 weeks, produced no effect on innate immune function or inflammation [25].

In metabolic syndrome volunteers, hesperidin (500 mg/d for 3 weeks) increased FMD, and reduced blood CRP, and sE-selectin [26]. Also in metabolic syndrome subjects, red orange juice containing 160 mg hesperidin for 1 week improved FMD, blood CRP, IL-6 and α-TNF, but not plasma NO concentration [27], while in moderately overweight men, hesperidin decreased diastolic blood pressure and improved microvascular endothelial reactivity post-prandially at the peak of hesperetin plasma concentration [28], and these changes were associated with a more anti-inflammatory blood leukocyte gene expression profile [29]. Human and animal studies on hesperidin have been reviewed [30]. In 42 volunteers with high cardiovascular risk factors, cocoa powder (40 g/day for 3 weeks) increased FMD, and reduced blood CRP, and IL-6 [31]. Also in patients with high CVD risk, bilberry juice decreased plasma CRP, IL-6, IL-15 and INF-gamma-induced monokines, but increased α-TNF, interpreted as effects on nuclear factor κB (NF-κB) [32].

2.1 Inflammation-related signalling pathways and kinase cascades

Most known signalling pathways related to inflammation involve members of the IL-1 and tumor necrosis factor (TNF) receptor families and the Toll-like recognition receptors (TLR) [33]. Activation of either of these receptors recruits adaptor proteins that further recruit signalling proteins, leading to activation of mitogen-activated protein kinases (MAPK) such as extracellular response kinases (ERK 1/2), Jun N-terminal kinase (JNK), p38 MAPK and inhibitor of nuclear factor κB kinases (IKK). MAPKs lead to phosphorylation of transcription factors such as activation protein (AP-1) and cAMP response element-binding proteins that bind to promoters of pro-inflammatory genes activating their transcription. In addition, MAPKs are able to induce post-transcriptional mechanisms to directly regulate pro-inflammatory gene expression. IKK is mainly related to NF-κB activation, recognised as a central player in inflammatory and immune responses [34, 35]. Both MAPK and IKK induce expression of IL-1β and TNFα, further amplifying the immune response within minutes [36] while TLR activation also results in synthesis of other pro-inflammatory factors such as IL-6 and IL-8. Both cytokine receptor- and TLR receptor-activation leads to enhancement of the phosphoinositide-3-kinase (PI3K) pathway and other related kinases such as Akt. Activation of Akt elicits several cellular effects such as stimulation of glycogen synthesis, inhibition of gluconeogenesis and stimulation of glucose uptake [37] and is involved in the insulin signalling cascade.

(Poly)phenols can influence these processes in several ways. For example, some lines of research suggest that inhibition of the PI3K/Akt pathway by quercetin can take place via direct inhibition of PI3K based on X-ray crystallographic analysis showing that quercetin fits into the ATP-binding site of PI3Kγ with a Kᵢ value of 0.28 μM. The direct binding of PI3K by quercetin inhibits downstream the PI3K/Akt pathway of signalling, including inhibition of AP-1 and suppression of NF-κB activation [38]. In addition, MAPKs are involved in vascular inflammation through the modulation of adhesion molecules (ICAM-1, VCAM-1, E-selectin) and chemotactic factor expression. Several studies showed that (poly)phenols such as resveratrol [39] and piceatannol [40] regulate these events through extracellular signal-regulated kinase (ERK) 1/2 and p38, and ERK 1/2 inhibition, respectively. Structural studies indicate that quercetin can also have an effect on the MAPK/ERK pathway due to binding to a pocket separate from, but adjacent to, the ATP-binding site of MAP2K1 [41]. This interaction would lead to the inhibition of phorbol ester-induced phosphorylation of ERK and downstream suppression of the activation of AP-1 and NF-κB. Hesperetin-3′-O-sulfate, hesperetin-3′-O-glucuronide and naringenin-4′-O-glucuronide (2 μM) significantly attenuated monocyte adhesion to TNFα-activated human umbilical vein endothelial cells (HUVECs) [42]. 4′-O-methyl (–)-epicatechin, its glucuronide and EC-4′-O-sulfate (0.2–1 μM), attenuated the adhesion of monocytes to endothelial cells by inhibition of NF-κB and MAPK phosphorylation [43]. In HUVECs, (+)-catechin, (–)-epicatechin, quercetin and resveratrol (0.001–10 μM) up-regulated both tissue-type plasminogen activator (tPA) and urokinase-type PA (u-PA) mRNA, resulting in sustained increased expression of surface-localized fibrinolytic activity [44]. TNFα induced up-regulation of VCAM-1, ICAM-1 and monocyte chemotactic protein-1 (MCP-1) and mRNA in human umbilical artery smooth muscle cells was attenuated by quercetin, but not quercetin-3′-O-sulfate, quercetin-3′-O-glucuronide and 3′-methylquercetin-3′-O-glucuronide [45]. In cultured rat aortic smooth muscle cells, quercetin-3′-O-glucuronide (10 μM) inhibited platelet-derived growth factor-induced cell migration and kinase activation [46]. Quercetin (15 μM) reduced the monocyte-binding properties of human aortic endothelial cells [47]. In HepG2 cells, (–)-epicatechin (10 μM) up-regulated NF-κB-binding activity [48], quercetin at the same concentration inhibited H₂O₂-induced NF-κB
activity [49], and quercetin attenuated NF-κB activation induced by TNF [50]. Quercetin protected β-cells from cytokine-induced damage partly through NF-κB [51]. In animal studies, a high doses of quercetin delivered i.p. attenuated NF-κB activation in the liver of streptozotocin-diabetic rats [52], and inhibited colitis in sodium dextran sulfate-treated rats [53].

### 2.2 Effects involving adipose tissue

Adipose tissue (AT) is considered an active endocrine organ able to send and respond to signals in order to modulate appetite, energy intake, insulin sensitivity, the endocrine and reproductive system, bone metabolism and inflammation, among other functions [21, 54, 55]. It has been suggested that reduction in weight and body fat percentage can decrease the concentration of circulating pro-inflammatory agents and increase anti-inflammatory molecules. Metabolically, the dense network of blood vessels present in AT serves for the systematic transport of lipids towards the adipocytes. On the other hand, these vessels also carry adipokines and adipocyte nutrients to meet the metabolic and physiological demands, and in fact pro-inflammatory signalling in the adipocyte is required for proper adipose tissue re-modelling and expansion [56]. However, in obesity, lipid storage capacity is reduced and enlargement of visceral adipose tissue is prominently affected, especially in the postprandial period. This process probably occurs because the volume of adipocytes in obese individuals has already reached its limit and cannot accumulate TAG efficiently [57]. In addition there is an increase in the rate of lipolysis during the fasting period [55]. Non-esterified fatty acids (NEFA) transport in hypertrophic adipocytes is reduced possibly due to the lack of stimulus generated by insulin and linked to less insulin receptors (IRs) exposed on the cell surface and restricted Glut4 translocation to the cell membrane. As a result, other tissues are exposed to excessive NEFA influx [56].

Adipokines excreted by the AT comprise proteins related to the immune system (e.g. TNF-α and IL-6), growth factors (e.g. transforming growth factor-β) and proteins of the alternative complement pathway (adipsin). Others are involved in blood pressure regulation (angiotensinogen), blood clotting (plasminogen activator inhibitor-1; PAI-1), glucose homeostasis (adiponectin, resistin, visfatin and leptin) and angiogenesis (vascular endothelial growth factor; VEGF), among several other actions [58]. Besides the fact that AT performs its own metabolic activities, the adipocytes release signals to other tissues and regulate their metabolism. Two mechanisms are suggested in the literature to explain the low-intensity chronic inflammatory process in relation to AT: adipocyte hypoxia and macrophage infiltration into AT [59]. It is hypothesised that the onset of hypoxia stimulates the release of inflammatory cytokines, chemokines and angiogenic factors (VEGF) as a way to increase the blood flow and stimulate vasculatisation. Increased expression of adhesion molecules in the endothelium of blood vessels, such as MCP-1, leads to an increased number of circulating monocytes that infiltrate into AT. In high glucose or advanced glycation end products, quercetin, epigallocatechin gallate (EGCG) and curcumin affected membrane fluidity and transmembrane potential of HUVECs and Jurkat T lymphoblasts, and attenuated the release of pro-inflammatory factors, such as MCP1 [60].

On the other hand, macrophage infiltration can be an important source of pro-inflammatory adipokines synthesised locally [61], thought to be mainly triggered by stress of the endoplasmic reticulum. It has been shown that TNFα inhibits the differentiation of adipocyte precursors and, similarly, IL-6 also inhibits adipocyte differentiation causing a vicious cycle of increased NEFA in blood. Increasing concentrations of NEFA are implicated in insulin resistance, also through effects on insulin receptor substrate-1 (IRS-1) decrease involving IRS-1 phosphorylation (ser307) catalysed by IKK and JNK. In adipocyte cells, PKCθ was also found to be actuated by fatty acids and contribute to IKK and JNK activation responsible for IRS-1 serine phosphorylation and degradation [62]. The activation of the novel PKC isoforms depends on the increase of diacylglycerol in the intracellular compartment, which is induced by increased lipid uptake. Upon activation, PKCe/ PKCb/PKCθ can actuate the serine phosphorylation of IRS-1 in muscle (PKCb and PKCθ) and liver (PKCe), leading to the insulin resistance phenotype [63]. Although adipose tissue only accounts for about 10% of insulin stimulated glucose disposal, it has a key role in directing whole-body glucose homeostasis and two plausible mechanisms have been postulated to explain this attribute. According to clinical data, pharmacological activation of PPARγ in adipose tissue improves its ability to store lipids; therefore it may be assumed it reduces the lipid burden and associated reactive oxygen species (ROS) in muscle and liver. This model involves activation of genes encoding molecules that promote a combination of lipid storage and lipogenesis leading to body-wide lipid repartitioning by increasing the triglyceride content of adipose tissue and lowering free fatty acids and triglycerides in the circulation, liver and muscle, thereby improving insulin sensitivity [64]. On another front, PPARγ-specific drugs alter the release of signalling molecules from fat, including leptin, TNFα, resistin and adiponectin, which by virtue of serum transport have far-reaching metabolic effects in other tissues [59].

Effects of polyphenols on PPARγ and downstream pathways have accumulated mainly from in vitro and animal studies (reviewed in [65]). Quercetin (IC50 = 3.0 μM) and luteolin (IC50 = 7.2 μM) were PPARγ antagonists at relatively low concentrations [66] based on an in vitro fluorescence competitive-binding assay, while mixtures of the aforementioned bioactives and others from an oregano extract were found to activate endothelial nitric oxide synthase (eNOS) dose dependently in HUVECs [66]. In human primary adipocytes, TNFα induced IL-6, IL-1b and IL-8, for example. Quercetin (10–60 μM) attenuated this through effects on phosphorylation of ERK1/2 and JNK, NF-κB-related transcriptional activity, PPARγ and serine phosphorylation...
of IRS-1 and protein tyrosine phosphatase-1B mRNA expression and its suppression of insulin-stimulated glucose uptake [67]. Mochizuki et al. [68] found that the vascular permeability of quercetin-3-O-glucuronide in human aortic endothelial cell inserts was dramatically increased by stimulation of interleukin (IL-1)-α, an inflammatory cytokine originating from macrophages, while in a study on mice, quercetin attenuated mast cell and macrophage infiltration into epididymal adipose tissue following a high fat diet [69]. Supplementation with 0.1% quercetin for 12 weeks modified the phenotype ratio of M1/M2 macrophages, lowered the levels of pro-inflammatory cytokines, and inhibited polarization and inflammation of mouse bone marrow-derived macrophages through an AMPKα1/SIRT1-mediated mechanism. According to others, the anti-inflammatory action of quercetin in the macrophages is due to inhibition of JNK activation during lipopolysaccharide-induced mitochondrial dysfunction in an adipocyte cell model [70, 71]. Overman et al. [72] ascribed these anti-inflammatory effects to suppression of NF-κB activation in agreement with other findings [67] reporting a decrease in TNFα-induced NF-κB transcriptional activity in primary human adipocytes and further attenuation of the TNFα-mediated suppression of PPARγ activity and PPARγ target genes. Similar effects were found for EGCG in macrophage foam cells [73] and these were linked to suppressed expression of CD36, a lipid co-transporter and a postulated receptor for lipoproteins. In rats, green tea polyphenols reduced fat deposits induced by a high fat diet, ameliorated hypo-adiponectinaemia and relieved high glucose-induced adiponectin decrease in visceral AT in vitro. The signalling pathway analysis indicated that PPARγ regulation mediated via the ERK1/2 pathway was involved [74]. (-)-Catechin, not naturally present but produced by heat treatment of green tea, was the most potent of the eight green tea (poly)phenols evaluated in promoting adipocyte differentiation in human bone marrow mesenchymal stem cells in a dose-dependent manner (1–10 μM) through PPARγ transactivation [75]. The multifaceted role of PPARγ on the interface of inflammation and obesity makes it difficult to dissect whether effects of bioactives related to this pathway act by enhancing downstream metabolic biomarkers or by improving the clinical signature of inflammation. In one of very few such human studies, the effect of consumption of polyphenol-rich cloudy apple juice (containing 40 mg total flavanols, 71 mg dihydrochalcone derivatives, 169 mg total phenolic acids and 4 mg total flavonols, daily for 4 weeks) on plasma parameters related to the obesity phenotype and potential effects of interactions between the apple juice and allelic variants in obesity candidate genes (PPARγ related) was assessed. The apple juice had no significant effect on plasma lipids, plasma adipokine and cytokine levels; however, it significantly reduced percent body fat. The IL-6-174 G/C polymorphism showed an interaction with body fat reduction induced by the apple juice. Solely in C/C, but not in G/C or G/G variants, a significant reduction in body fat after 4 weeks of apple juice intervention was detectable [76]. This study highlights the importance of inter-individual variability in nutritional interventions.

2.3 Oxidative mechanisms, insulin signalling and mitochondrial dysfunction

It is well known that oxidative stress is a common characteristic in people with the metabolic syndrome phenotype [77]. The mechanisms involved in elevation of oxidative stress and inflammatory burden include increased production of superoxide anion via the NAD(P)H pathway, deregulation of leptin levels in adipocytes that stimulate directly ROS production such as hydrogen peroxide (H2O2), hydroxyl radicals (HO·) and mitochondria-related metabolism of energy substrates. Furthermore, sustained high glucose levels lead to generation of advanced glycation end products which accumulate in the vessel wall, and, through interactions with its receptors, activate NF-κB via MAPKs and lead to the transcription of pro-inflammatory factors [78]. Excess energy substrate in the form of glucose or fatty acids enter the citric acid cycle resulting in the generation of excess mitochondrial NADH and consequently ROS [79]. When excessive NADH cannot be dissipated by oxidative phosphorylation, the mitochondrial proton gradient increases and single electrons are transferred to molecular oxygen forming superoxide anions. Although low levels of H2O2 may be required for normal cellular functioning, for instance to terminate PI3K signalling through protein tyrosine phosphatases, exaggerated mitochondrial ROS generation results in perturbation of the PI3K pathway, insulin resistance [80] and deregulation of uncoupling proteins (UCP) that normally act as oxidative stress protective agents. Subsequently mitochondrial oxidative phosphorylation is uncoupled from ATP synthesis, followed by an increase in the cellular NADH/NAD+ ratio through heightened glycolysis. Furthermore, adipocyte O2 consumption may be inhibited by ROS, since pyruvate and N-acetyl cysteine stimulated respiration in adipocytes in vitro. ROS inhibition of O2 consumption may explain the difficulty in identifying effective strategies to increase fat burning in adipocytes. Stimulating fuel oxidation in adipocytes by decreasing ROS may provide a novel means to shift the balance from fuel storage to fuel burning. Aggravation of mitochondrial dysfunction in a variety of cells, combined with endoplasmic reticulum stress in the adipocyte with related unfolded protein response, converge in a systemic pro-inflammatory state [81].

In HUVECs, apoptosis induced by high glucose was inhibited dose-dependently by quercetin sulfate/glucuronide (300 nM), in addition to H2O2 quenching, inhibition of JNK and of caspase-3 activity [82]. H2O2-decreased total intracellular glutathione and JNK and p38 MAPK phosphorylation were blocked by quercetin ≥10 μM [83]. Quercetin reduced high glucose-induced HUVEC proliferation, and increased
apoptosis. HSP27 phosphorylation is important in mediating the proliferation and apoptosis of HUVECs induced by high glucose, and PI3K/Akt and ERK1/2 are important signalling pathways that contribute to HSP27 phosphorylation. Quercetin or quercetin-3’-O-sulfate (10 μM) inhibited, by an endothelium-independent action, receptor-mediated contractions of the porcine isolated coronary artery [84]. (−)-Epicatechin and (+)-catechin (0.5–10 μM), and to a lesser extent their methylated and glucuronidated metabolites, protected against H2O2-induced intracellular oxidative stress [85]. Quercetin is rapidly taken up by cells and accumulates in various cell compartments, with remarkable concentrations found in mitochondria [86, 87]. Intra-mitochondrial quercetin appears to be functional for prevention of mitochondrial damage as well as for redistribution to the cytosol, when the fraction of the flavonoid therein retained is progressively consumed either by cell-permeant oxidants such as peroxynitrite or by activation of plasma membrane oxidoreductases. It has also been postulated that inflammation enhances intracellular β-glucuronidase leading cells exposed to glucuronide conjugates of quercetin to release the more bioactive aglycone. The same situation could apply for other (poly)phenols [88, 89]. Extracellular β-glucuronidase secreted from macrophages and in the vascular bed can also lead to deconjugation of the glucuronide conjugates of (poly)phenols and deliver the aglycone at a higher local concentration, which due to its higher lipid solubility accumulates in tissues [89, 90]. In support of this notion, a recent acute human study reported effects of quercetin in hypertensive subjects related to increased plasma glutathione levels, an antioxidant biomarker; these effects were proportional to the bioavailability of quercetin and the rate of deconjugation of the glucuronide in tissues [91]. Mitochondrial proton F0,F1-ATPase synthesises ATP during oxidative phosphorylation, and partial inhibition of ATPases can affect the energy balance and metabolism in cells. Quercetin has been known to interact with ATPases since the 1970s [92, 93], and resveratrol is also an inhibitor [94]. After treatment with quercetin for 4 weeks at 20 mg/kg/day, kidney Na, K-ATPase affinity for sodium was decreased in both normotensive and hypertensive rats [95]. The inhibition constant (competitive) for quercetin on Ca2+-ATPase from rabbit skeletal muscle was 8.7 μM [96].

2.4 Effects on insulin resistance through β-cell function

It has been suggested that pancreatic islet inflammation is associated with very early insulin resistance, while there is strong evidence showing that the recruitment and activation of 1L1β-producing macrophages mediate islet inflammation. In β-cells, mitochondrial activity is more than two times greater than in any other cell type as mitochondrial ATP generation plays a pivotal role in insulin secretion of pancreatic β-cells. Increased mitochondrial ATP production in response to hyperglycaemia closes the ATP sensitive potassium channels, leading to membrane depolarization, opening of voltage-sensitive calcium channel, calcium ion influx and insulin granule exocytosis [97]. The increased expression of UCP2 is also responsible for affecting glucose-induced insulin secretion due to the reduction of ATP production [81]. β-cells are poor in antioxidant enzymes such as superoxide dismutase, glutathione peroxidase and catalase, and therefore particularly sensitive to ROS and reactive nitrogen species [98] amplified by hyperglycaemia and increased levels of fatty acids. Apoptosis of β-cells further accentuates the vicious cycle linking β-cell failure, mitochondrial dysfunction and insulin resistance through pronounced oxidative damage. To counteract these insults, most cells, including β-cells, have intricate mechanisms of defence against ROS toxicity and among these, the transcription factor NF-E2–related factor 2 (Nrf2) is a pivotal component. In response to oxidative stress, activation of Nrf2 dramatically increases intracellular antioxidant potential by directly increasing the transcription of many so-called antioxidant enzymes.

(Poly)phenols and pancreatic β-cell function have been recently reviewed [99]. Green tea catechins were reported to have a beneficial role in regulation of insulin secretion in β cells isolated from fed adult male Wistar rats. EGCG and epicatechin gallate (but not epigallocatechin or epicatechin, source not specified) were potent inhibitors of glutamate dehydrogenase (GDH) activity with ED50 values of ~300 nM. Glutamate serves as a mitochondrial intracellular messenger when glucose is being oxidized, and EGCG did not affect glucose-stimulated insulin secretion under high energy conditions where GDH was fully inhibited [100]. Cai et al. [101] evaluated the effect of EGCG on glucose-induced toxicity in a rat pancreatic β-cell line, rat insulinoma (RIN)-m5F cells, and showed that EGCG (0.1 and 10 μM) treatment improved insulin secretory function and viability of β-cells under conditions of glucotoxicity. These effects were at least partly mediated through increased expression of IRS-2, Akt and FOXO1 and an enhancement of mitochondrial mass and functional integrity in high glucose.

Apart from enhancing mitochondrial status, other protective effects of (poly)phenols such as flavanols, quercetin, luteolin and others in vitro have been recently reviewed [102] and seem to be mainly mediated through suppression of inflammatory cytokine production and ROS/reactive nitrogen species. Direct binding of (poly)phenols to receptors involved in signalling pathways discussed earlier and enzyme inhibition of oxidative enzymes account for some of the mechanisms involved. However, there are few human studies assessing β-cell functionality, as relevant biomarkers have not been strictly defined. Recently curcumin has emerged as an attractive nutritional bioactive in the field of diabetic nutrition. This assertion comes after a 9-month study, involving a pre-diabetic population, which demonstrated that curcumin treatment could not only lower haemoglobin A1c (HbA1c) and homeostasis model assessment of insulin resistance (HOMA-IR) levels (a measure of insulin sensitivity), but also decelerate the deterioration of pre-diabetes to type
2 diabetes [103]. Curcumin (1–100pM) and resveratrol (0.1–10 μM) were reported to enhance pancreatic β-cell function by regulating the activity of phosphodiesterases, which degrade cAMP and cGMP, thereby modulating various cellular signalling pathways previously linked to regulation of insulin secretion in islets [104]. Linking these data to the human study outcomes remains quite challenging as curcumin is quite unstable under certain cell culture conditions, and the controversy surrounding resveratrol clinical outcomes warrants more well-controlled mechanistic work. Frequent spikes of post-prandial glucose can affect insulin secretion and β-cell dysfunction accelerating the onset of diabetes. Towards that direction, nutritional interventions with low glycaemic index foods could lead both to enhancing insulin secretion and suppressing oxidative species in the vasculature, through a delay in the release of glucose to the bloodstream and available substrate for oxidation in mitochondria, at the same time of a high lipid bolus [19].

3 Effects of (poly)phenols on blood pressure, platelet aggregation and endothelial dysfunction via interactions of (poly)phenols with endothelial and smooth muscle cells

It remains unclear whether elevated levels of free radicals initiate the development of hypertension or are a consequence of the disease process itself, or both [105]. Vascular alterations may be potentiated in several ways, including direct damage to endothelial and vascular smooth muscle cells (VSMC), as the endothelium plays a crucial role in modulating vascular tone by synthesizing and releasing endothelium-derived relaxing factors, including vasodilator prostaglandins, NO and endothelin-dependent hyperpolarization (EDH) factors, as well as endothelium-derived contracting factors. For example, endothelium-derived NO inhibits growth factor-stimulated proliferation and migration of VSMC [106]. As early as in 1988 [107, 108], it was postulated that a diffusible substance released by the endothelium causes hyperpolarization and relaxation of the underlying VSMC, attributed to the existence of putative EDH factors. It is widely accepted that the nature of EDH factors varies depending on species and vascular beds examined, including epoxycosoatrienoic acids, metabolites of arachidonic P450 epoxygenase pathway, electrical communication through gap junctions, K+ ions, hydrogen sulfide (H2S), and H2O2 (reviewed in [109]).

NO predominantly modulates the tone of large conduit vessels and the contribution of NO decreases as the vessel size decreases, whereas that of EDH increases as the vessel size decreases, a phenomenon that is well preserved from rodents to humans. Thus, EDH, rather than NO, plays a dominant role in small resistance vessels where blood pressure and organ perfusion are finely regulated. It has been demonstrated that Akt1 is involved in the depolarisation process preceding the activation of NADPH oxidase (NOX) and partnering with PKC to mediate these effects [97].

Several recent reviews have summarised the effect of (poly)phenols and (poly)phenol-rich foods on blood pressure, platelet aggregation and endothelial dysfunction in volunteers [19, 110–114], and the evidence has resulted in one of the few current European Food Safety Authority (EFSA) allowed claims on (poly)phenols ((−)-epicatechin). In a randomized, placebo-controlled, crossover trial on healthy men, 200 mg quercetin increased plasma S-nitrothiols, plasma nitrite and urinary nitrate, and reduced both plasma and urine endothelin-1, but did not change isoprostanes [115]. In the same study, (−)-epicatechin lowered plasma endothelin-1, S-nitrothiols and nitrite, and urinary nitrate, but EGCG at the same dose did not show any of these changes [115].

Many animal studies have also been performed, for example (−)-epicatechin (6 mg/kg body weight) decreased systolic blood pressure in spontaneously hypertensive rats, but there was no effect in normotensive Wistar–Kyoto rats [116]. However, the mechanism of action is complex, and is likely to result from small effects on multiple targets, since many factors regulate these processes. Realistic potential targets affected by (poly)phenols are NOX, endothelin production, arginine, eNOS and NO metabolism (Fig. 1) and these are discussed below. In healthy volunteers, a high flavanol cocoa drink led to a lower arginase activity in erythrocytes [117]. Many of the experiments on endothelial function have been performed on HUVECs in vitro, and some are on the underlying smooth muscle cells. Signals between the two cell types are important for determining vasoconstriction, associated with increased blood pressure, and vasodilation, and resulting lowered blood pressure. Some of the molecular mechanisms, focusing on those that might be modulated by (poly)phenols, are shown in Fig. 1. In addition, HUVECs exhibit some capacity to metabolise (poly)phenols. For example, (−)-epicatechin is methylated and metabolised to 3-methyl(−)-epicatechin-7-O-glucuronide and 3-methyl(−)-epicatechin-7-O-sulfate [118]. This metabolism can modify the biological activity of the parent (−)-epicatechin [119].

3.1 eNOS and NO bioavailability

Although the underlying cause of endothelial dysfunction is multifactorial, a key player is impairment of NO bioavailability. NO is considered a vasodilator molecule, produced by the conversion of L-arginine into L-citrulline via a family of NO synthases (NOSs). There are three NOS isoforms, including neural NOS (nNOS, NOS1), inducible NOS (iNOS, NOS2) and endothelial NOS (eNOS, NOS3, Ca2+-calmodulin-dependent isoform). The latter is the dominant NOS isoform in blood vessels [120] and is the most important in generating H2O2/EDH in the endothelium as mentioned above. NO and eNOS also participate in the neo-vascularization process, via mobilization of progenitor cells from brown marrow stem cell niches to the peripheral circulation, where they are
involved in vascular repair at sites of injury through their differentiation in mature endothelium. The diverse roles of NOS systems in the endothelium depend on blood vessel size; NOS mainly serves as an NO-generating system to elicit soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP)-mediated relaxations in large conduit vessels, and a superoxide-generating system to cause EDH/H$_2$O$_2$-mediated responses in small resistance vessels [121]. The potential importance of the physiological balance between NO and EDH/H$_2$O$_2$ through the diverse functions of the endothelial NOS system is reflected in the commonly reported failure to show effects in clinical trials with antioxidant approaches.

(Poly)phenols have been reported to have several effects on these systems. Quercetin aglycone (but not conjugates) significantly reduced both eNOS protein and gene expression in HUVEC, as did TNFα. In the presence of TNFα, the aglycone caused further reductions in eNOS, whereas the metabolites were without effect in either TNFα-stimulated or unstimulated cells [122]. HUVECs were incubated with platelets, pre-treated with various doses of (poly)phenols, from peripheral artery disease patients. This gave a decrease of sCAMs release and an increase of p-eNOS and NO bioavailability reducing endothelial activation induced by activated platelets [123]. Hesperetin increased NO release from HUVECs in a dose-dependent manner and up-regulated eNOS expression [124]. Hesperetin stimulated phosphorylation of Src, Akt, AMPK and endothelial NO synthase to increase NO production. Hesperetin attenuated the TNFα-increased adhesion of monocytes and expression of vascular cell adhesion molecule-1 [26]. Effects of quercetin on eNOS are contradictory, but appear to be concentration dependent. At lower concentration (<10 μM), eNOS activity is increased. For example, quercetin and quercetin-3-O-glucuronide (5–10 μM) protected isolated C57BL mouse aortic rings against hypochlorous acid-induced endothelial dysfunction, and this effect was blocked by AMPK inhibition. These compounds also activated AMPK and eNOS in human aortic endothelial cells, and increased nitrite and S-nitrosothiols in the medium [125]. At higher concentrations of quercetin (30–100 μM), eNOS activity was decreased in bovine aortic endothelial cells by decreasing Ser617 phosphorylation, and also ser473 Akt phosphorylation [126]. Increasing eNOS results in an increase in NO. For example, in endothelial cells, quercetin induced phosphorylation of eNOS (ser1179), PKA, Akt and ERK1/2, and increased NO concentration [127]. In vivo, in spontaneously hypertensive rats, quercetin reduced the increase in blood pressure and heart rate, and prevented the increase in NADPH-induced superoxide production and lowering of eNOS activity (although eNOS protein was increased in this model in contrast to the activity) [128].

3.2 Arginase

In several cell types, L-arginine transport has been considered as a rate limiting factor for NO synthesis. HUVECs, endothelial cells from human placental microvessels, human saphenous veins and human endothelial progenitor cells (hEPC) are all able to transport L-arginine and synthesize NO [129]. Emerging evidence suggests that upregulation of arginase is of central importance for reduced NO bioavailability due to competition for the substrate L-arginine between arginase and the eNOS. Arginase is also associated with increased
oxidative stress, further impairs NO bioavailability. Upregulation of arginase has thereby been suggested to be a key factor driving endothelial dysfunction in diabetes. There are only limited examples where (poly)phenols affect arginase activity. In HUVECs, cocoa flavanols lowered both arginase-2 mRNA expression and activity, and this was supported in the same paper by a study on rats, where flavanol-rich cocoa decreased arginase activity in rat kidney [117].

3.3 NADPH oxidase

NADPH oxidase (NOX) is a major source of ROS in the vasculature, especially in response to high glucose. NOX1 was shown to be involved in angiotensin-II-mediated hypertension using NOX1-deficient mice [130]. Sustained activation of NOX in diabetes leads to lowered intracellular NADPH, an essential cofactor for eNOS [131]. High glucose in HUVECs leads to upregulation of the p47\textsuperscript{phox} subunit of NOX through NF-кB activation [132, 133] and oxidative stress markers. (−)-Epicatechin glucuronide and 3/4-methyl (−)-epicatechin, but not (−)-epicatechin, inhibited NOX activity in HUVEC cells [119]. Quercetin and quercetin-3-O-glucuronide (1 \(\mu\)M) inhibited NOX activity in vascular smooth muscle cells ex vivo from both spontaneously hypertensive rats and normotensive Wistar Kyoto rats, and this effect was abolished by the β-glucuronidase inhibitor, saccharolactone, indicating that the active aglycone is generated in situ [134]. (−)-epicatechin (0.3–10 \(\mu\)M) increased NO in HUVECs but did not affect eNOS mRNA [135]. HUVECs treated with oxLDL, but not with LDL, exhibited decreased intracellular NO and superoxide overproduction, prevented by quercetin or resveratrol. Oxidised LDL also up-regulated leukocyte recruitment and adhesion genes, which was abolished by resveratrol, but not quercetin (10 \(\mu\)M), which even increased some of the genes [136]. O-methylated (−)-epicatechin suppressed superoxide generation through inhibition of endothelial NOX activity, and the effect was even more potent than the commonly used positive control, apocynin [137].

3.4 Endothelin

Endothelin-1 (ET-1) is a small peptide with potent vasoconstrictor activity, and its production by endothelial cells is stimulated by several factors including insulin, hypoxia, oxidized LDL, or pro-inflammatory cytokines [138]. ET-1 also modulates cell growth, and is possibly involved in the development and progression of atherosclerosis and hypertension. In HUVECs, resveratrol and quercetin (0.1 \(\mu\)M), but not ferulic acid, decreased expression of endothelin-1 [139]. Quercetin and quercetin-3′-O-sulfate (1 \(\mu\)M) attenuated ET-1-induced endothelial dysfunction in Wistar rat thoracic aortic rings, and at higher concentrations, together with quercetin-3′-O-glucuronide, inhibited NOX-derived superoxide release [140]. Thrombin and activated platelets stimulated the release of ET-1 from HUVECs, and this was inhibited by quercetin (0.5–50 \(\mu\)M) that also promoted the formation of cGMP [141].

Quercetin aglycone (but not conjugates) significantly reduced ET-1 expression in TNFα stimulated and unstimulated HUVECs, but quercetin-3′-O-sulfate caused a moderate increase of ET-1 in TNFα stimulated cells [122]. ET-1 increased the phenylephrine-induced contractile response in the aortic rings from male Wistar rats, and this was attenuated by quercetin and isorhamnetin (1 and 10 \(\mu\)M). In the same system, ET-1 induced upregulation of NOX p47phox protein and intracellular superoxide and eNOS uncoupling, again attenuated by quercetin [142].

3.5 ACE inhibition

Endothelial cells express angiotensin-converting enzyme (ACE) and angiotensin AT1 and AT2 receptors. ACE activity inhibition may result in a decrease of blood pressure by causing blood vessel constriction through conversion of angiotensin I to angiotensin II, which binds to AT1 receptors and receptors expressed on smooth muscle cells, and also stimulates the release of aldosterone [142]. Although angiotensin II can also induce vasorelaxation by stimulating AT2 receptors and upregulating eNOS and inducible NO synthase (iNOS) expression, vasoconstriction is predominant in most circumstances as it reduces eNOS-derived NO by promoting eNOS uncoupling through monocyte-dependent S-glutathionylation [143]. Furthermore, angiotensin II and aldosterone promote inflammation by inducing COX-2 expression, fibrosis and endothelial dysfunction with upregulation of adhesion molecules via TNFα, considered important for the development of atherosclerotic lesions and plaque rupture [144].

There are limited convincing reports of inhibition of ACE activity by (poly)phenols at physiologically relevant concentrations. ACE was not inhibited by (supra)physiological concentrations of flavanols and procyanidins [145, 146]. Quercetin-3-O-glucuronide (1 and 10 \(\mu\)M) blocked angiotensin-II induced JNK activation in rat aortic smooth muscle cells [147]. Similarly, the reduction in the angiotensin II-induced endothelial expression of chemokines and adhesion molecules by EGCG occurs via ERK1/2 and p38 inhibition [148]. A flavonoid-rich apple peel extract, and also quercetin-3-O-glucuronide and quercetin-3′-O-sulfate (indicated as the 3-O-sulfate in the paper but most probably is the 3′-O-sulfate), inhibited ACE, but a high concentration was needed (IC\textsubscript{50} values of 27 and 131 \(\mu\)M, respectively) [149].

3.6 Protease activity

The extracellular matrix (ECM) plays an important structural and functional role in maintaining proper contractility and integrity of arterial walls. The composition and structure of
ECM undergoes significant changes during the atherosclerotic process as a result of compromised regulation of the matrix metalloproteinase (MMPs) network and modifications of matrix component synthesis and deposition. Denudation of the arterial wall surface from endothelial cells and exposure of the underlying ECM to blood dramatically increases monocyte binding to injured sites and their arterial wall invasion. Leukocyte adhesion to ECM components is mediated by cell surface–expressed integrins with different specificity and affinity [47]. Angiotensin II increases receptors for vascular endothelial growth factors and MMPs that may account for increases in endothelial permeability and vascular remodelling [150]. Genistein, apigenin and 3-hydroxyflavone inhibited in vitro angiogenesis, in part via preventing vascular endothelial growth factor/basic fibroblast growth factor (VEGF/bFGF)-induced MMP-1 and urokinase-type plasminogen activator (uPA)-plasmin system expression and the activation of pro-MMP-2, and via modulating their inhibitors, TIMP-1 and -2, and PAI-1 [151]. (+)-Catechin, (−)-epicatechin, B2 dimer and gallic acid (<1 μM) inhibited dipetidyl-peptidase 4 (DPP4) activity in HUVEC by 5–10 % [152].

Angiotensin II–induced contractile activity of cultured human ASMC embedded in a collagen matrix was inhibited by catechins, dependent on the number of gallate groups, and this correlated with inhibition of matrix metalloproteinase-2 expression [153].

3.7 Telomere length, oxidative stress and sirtuins; role in vascular ageing

The emerging role of cellular DNA damage and the link to endothelial vascular complications stems from association studies showing that telomere length reflects the lifelong accumulating burden of increased oxidative stress and inflammation [154].

The epigenetic changes of histone and nonhistone protein deacetylation are catalysed by sirtuins (SIRTs), a family of proteins with seven isoforms that all possess a common, highly conserved catalytic domain and an NAD$^+$-binding site. The role of SIRTs in vascular homeostasis has been recently reviewed [106,155] and especially in relation to the actions of the (poly)phenol resveratrol; a known SIRT1 activator in various models and settings [156, 157]. SIRT1 is highly expressed in the vasculature during blood vessel growth and partly controls the angiogenic activity of endothelial cells via a deacetylation-dependent inactivation of FoxO1, a crucial negative transcriptional regulator of blood vessel development; thus SIRT1 promotes cell survival under oxidative stress and inhibits apoptosis. Inhibition of SIRT1 induces premature senescence-like growth arrest in HUVECs whereas overexpression or activation of SIRT1 prevents premature senescence induced by H$_2$O$_2$. In addition, protection against oxidative stress-induced cellular senescence is mediated by downregulation of p66Shc, a stimulator of mitochondrial production of ROS and against oxidative stress-induced EPC apoptosis by promoting the ubiquitination and degradation of FoxO3a.

SIRT1 has also been linked to vascular health by activation of eNOS through deacetylation of lysine residues in the calmodulin-binding domain. In SIRT1, SMC acts as a modulator of neointima formation and protects against DNA damage, medial degeneration, atherosclerosis and hypertension via repression of AP-1 activity and decreased expression of cyclin D1 and MMP-9 [158]. In endothelial cells, SIRT1 is reported to act as an NF-κB suppressor and its downstream pro-inflammatory signalling pathways leading to the reduced expression of chemokines such as TNFα, MCP-1 and interleukins. SIRT1 activation was shown to inhibit cholesterol uptake and macrophage foam cell formation impeding infiltration of inflammatory cells to the sub-endothelial space. The beneficial effects of ACE inhibitors in endothelial cells were also partly ascribed to a p38-SIRT1 crosstalk [142]. However it is worth noting that, under basal conditions, SIRT1 may undergo post-translational modifications that can restrict its activities, such as serine phosphorylation on various sites (ser27, ser47, ser659 and ser661) that is mainly regulated by protein kinase CK2 and [NK] [159].

The “French paradox” was inaugurated in the early 1990s [160] mainly related to the conundrum of a diet high in atherogenic factors with a moderate consumption of alcohol. Wine (poly)phenols have attracted substantial research interest since, in 2003, Howitz et al. [161] reported resveratrol as a potent activator of SIRT1; and although the data has been challenged [162], extensive in vitro and animal research since suggests a role for (poly)phenols in inflammation through interplay with SIRT1 and associated pathways [156, 159] or through indirect enhancement of oxidative status in compromised models of disease. In a recent study in endothelial cells following palmitate-induced insulin resistance, 0.1–10 μM resveratrol restored the IRS-1/Akt/endothelial NO synthase signalling pathway by suppressing IKKα/B/ NF-κB phosphorylation, as well as TNFα and IL-6 production. Furthermore, resveratrol effectively inhibited the mitogenic actions of insulin by decreasing the secretion of ET-1 and PAI-1, and positively regulated SIRT1 activation, which contributed to the inhibition of inflammation implicated in endothelial insulin resistance. Stimulation with palmitate and long-term fructose feeding introduced impaired insulin-mediated vessel dilation in rat aorta, whereas pre-treatment of excised and prepared aortic rings with resveratrol (0.1–10 μM) or treatment of rats with 5 or 20 mg/kg resveratrol produced similar effects [163].

Other studies also showed that 2.5 mg/kg body wt/day of resveratrol for 15 days ameliorated endothelial dysfunction by regulating VEGF, eNOS, caveolin-1 and haem oxygenase (HO)-1 [164] in diabetic rats, while a dose of 20 mg/kg resveratrol for two weeks led to neovascularization of the hyper-cholesterolaemic myocardium of rats and conferred protection against myocardial injury caused by ischemia-reperfusion through the same mechanism [165]. These studies are only a few of many other animal studies and...
others in vitro in the literature showing beneficial effects of resveratrol in the endothelium through NO-related mechanisms [166,167].

Nevertheless, data from human studies linking to positive translational effects remain scarce. A study recently showed no beneficial effects on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure following a 12-week supplementation of 500 mg resveratrol in a randomised double-blinded placebo-controlled clinical trial of 50 NAFLD patients [168]. In contrast, 6 weeks supplementation with 500 mg resveratrol improved quality of life and clinical manifestation of colitis at least partially through inflammation reduction in patients with ulcerative colitis [169]. Resveratrol supplementation significantly decreased serum inflammatory markers, activity of NF-κB in peripheral blood mononuclear cells (PBMC) and plasma levels of TNFα and hs-CRP. In another randomized, double-blind, placebo-controlled trial of 12 weeks of resveratrol supplementation (75 mg/day) in 30 non-obese, postmenopausal women with normal glucose tolerance, no metabolic effects or inflammatory markers were demonstrated and resveratrol did not affect SIRT1 and other related pathways in either skeletal muscle or adipose tissue biopsies of volunteers [170]. These conflicting data reflect challenges when translating pre-clinical findings to improved patient outcomes and only modest reductions in the degree of inflammatory parameters based on direct measurement of the plasma levels of well-known pro-inflammatory markers have been reported [171]. Other (poly)phenols such as quercetin are known to activate SIRT1 in the endothelium to a lesser extent and the effects are dose-dependent. For example, quercetin (2.5–10 μM) suppressed oxLDL-induced endothelial oxidative injuries by activating SIRT1 and modulating the AMPK/NADPH oxidase/AKT/endothelial NO synthase signalling pathway [172]. However these results have not been tested in the clinical setting. Other indirect mechanisms through which quercetin and other (poly)phenols such as luteolin and apigenin could contribute to enhancing NAD⁺ availability and activating SIRT1 relieving mitochondrial stress is through inhibition of NAD⁺-consuming enzymes such as the poly(ADP-ribose) PAR polymerase-1 CD38 NAD⁺ase [173–175].

4 Modulation of intracellular superoxide and plasma uric acid via inhibition of xanthine oxidoreductase

Elevated blood uric acid (hyperuricaemia) is a major risk factor for gout [160], diabetes [176], obesity [177] and hyperglycaemia [178,179], and is exacerbated by dietary purines, alcohol and fructose [180–182]. Insulin resistance is also related to hyperuricaemia [183] and metabolic conditions such as non-alcoholic fatty liver disease increase plasma uric acid [184]. Uric acid is a product of several endogenous cellular biochemical reactions (Fig. 2), where xanthine oxidoreductase (XOR; dehydrogenase: EC 1.1.1.204; oxidase: EC 1.1.3.22) is the final step in the formation of uric acid from xanthine and hypoxanthine, and is a source of intracellular superoxide. It is a complex protein and requires molybdenum, flavin adenine dinucleotide and iron-sulfur redox complexes for activity, and is particularly abundant in liver and small intestine [185]. Whether the product is hydrogen peroxide or superoxide depends on the biochemical form of the enzyme generated through intracellular processing. The product, superoxide, reacts with NO to form peroxynitrite, which has several deleterious activities, and also changes the bioavailability of
NO. In endothelial cells, peroxynitrite also oxidises tetrahydrobiopterin (a cofactor for eNOS), causing uncoupling of eNOS and endothelial dysfunction [131]. Over-activity of xanthine oxidoreductase leads to production of excess uric acid and superoxide, both with negative implications.

Quercetin and other flavonoids were identified as inhibitors of XOR over 60 years ago [186], and subsequently isorhamnetin and quercetin glucuronides were also shown to inhibit potently [187, 188]. Interaction with XOR is strongly dependent on the chemical structure and shape of the molecule, since chrysin, luteolin, kaempferol, quercetin, myricetin and isorhamnetin, were potent inhibitors, whereas isoflavones and anthocyanidins were less effective [189]. For apigenin, the bicyclic benzopyranone ring stacked with the Phe\textsuperscript{214} residue of XOR, the phenolic group interacted with multiple XOR hydrophobic amino acids, and the 3-hydroxyl group as present in quercetin slightly diminished the binding strength [190]. The important chemical aspects of flavonoids required for XOR inhibition have recently been summarised [191].

Serum uric acid in mice given a very high dose of quercetin (100–400 mg/kg body weight) were elevated, but these authors failed to show inhibition of XOR by quercetin in vitro, despite observing allopurinol inhibition as a positive control [192]. On the other hand, in rodents made hyperuricaemic by intraperitoneal injection of potassium oxonate, quercetin (5 mg/kg) for 2 weeks significantly reduced serum uric acid, paralleled by an inhibition of hepatic XOR activity [193]. Oral administration of various flavonoids including quercetin (50 and 100 mg/kg) for 3 days to potassium oxonate-induced hyperuricaemic mice reduced both blood and hepatic uric acid, again with inhibition of XOR [194].

Very few human intervention studies have been reported on (poly)phenols or (poly)phenol-rich foods where plasma uric acid is the primary outcome. Our recent study on mildly hyperuricaemic males showed an 8% reduction in plasma uric acid after consumption of 500 mg quercetin aglycone per day for 1 month [195], with the equivalent bioavailability of ~100 g red onions [196]. In studies where uric acid was measured, but not as a primary outcome, the results are mixed, and none of the studies selected volunteers with higher than average plasma uric acid. In healthy volunteers, supplementation of diets with 50, 100 or 150 mg/day quercetin aglycone for 2 weeks [197], or with a blueberry–apple juice mixture (97 mg quercetin/litre) for 4 weeks [198] gave no change in plasma uric acid. In stable type 2 diabetic patients, 76-110 mg of flavonols (mostly quercetin from 400 g of onions, and tomato sauce) and six cups of tea daily for two weeks gave no change in plasma uric acid [199]. Likewise, in smokers, six cups (900 mL) of black or green tea, or a supplement of 3.6 g of green tea (poly)phenols per day for 4 weeks elicited no change in plasma uric acid [200].

Although the number of relevant studies is too small to conclude, it is tempting to speculate that the effect of (poly)phenols, in particular quercetin, is to lower the blood levels of uric acid only when elevated levels are present at the start of the intervention. This hypothesis needs to be thoroughly tested, and we suggest that this is a priority for future work.

5 Future perspectives

Once early vascular ageing is defined, it remains to be determined whether interventions, such as by targeting the different pathways or elements, could slow down the process and prevent further deterioration. Pharmacological agents, including angiotensin-converting enzyme inhibitors, angiotensin II type 1 blockers, aldosterone antagonists and statins, are able to reduce arterial stiffness. However there are still no pharmaceutical agents that specifically target the vascular endothelium, and the main clinical advice remains to increase physical activity in combination with nutritional interventions. Although in vivo detection and targeting of senescent endothelial cells are still being investigated, it is likely that therapeutic strategies based on enhancing endothelial stress and preventing oxidative damage through the molecular avenues discussed would constitute an innovative treatment, perhaps by nutritional means, for slowing down vascular ageing. After all, the evidence that (poly)phenols may deliver a maximised effect at sites of inflammation has been proposed for quercetin as discussed above. In addition, nutritional intake implies that the body is exposed to (poly)phenols on a regular basis, which can exert an effect without any need for a “treatment” as such. One of the key aspects is that effects are most predominant when one or more biomarkers are suboptimal. Nevertheless, future studies should have enough power to detect differences, a range of doses and combinations should be tried, long-term studies should be designed and the participants should be well characterized. These studies should then be backed up by mechanistic studies in vitro.

A.K. and G.W. are funded by the ERC advanced grant “POLY-TRUE?” (322467) and the EU framework 7 project BACCHUS “Beneficial effects of dietary bioactive peptides and polyphenols on cardiovascular health in humans,” grant agreement number 312090.

GW has recently, or currently, received research funding from Nestle and Florida Department of Citrus, and conducted consultancy for Nutrilite, USA, and Suntory, UK.

6 References

[1] Ames, B. N., Shigenaga, M. K., Hagen, T. M., Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA 1993, 90, 7915–7922.
[2] Sies, H., Total antioxidant capacity: appraisal of a concept. J. Nutr. 2007, 137, 1493–1495.
[3] Ostan, R., Lanzarini, C., Pini, E., Scurti, M. et al., Inflammaging and cancer: a challenge for the Mediterranean diet. Nutrients 2015, 7, 2589–2621.
[4] Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P., Tognolini, M. et al., Dietary (pol)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid. Redox. Signal. 2013, 18, 1818–1892.

[5] Williamson, G., in Erdman, J. W., Jr., Macdonald, I. A., Zeisel, S. (Eds.), Present Knowledge in Nutrition, Wiley-Blackwell Iowa, USA, 2012, p. 419.

[6] Stalmach, A., Mullen, W., Barron, D., Uchida, K. et al., Metabolite profiling of hydroxycinnamate derivatives in plasma and urine after the ingestion of coffee by humans: identification of biomarkers of coffee consumption. Drug Metab. Dispos. 2009, 37, 1749–1758.

[7] Farrell, T. L., Gomez-Juaristi, M., Poquet, L., Redeui, K. et al., Absorption of dimethoxycinnamic acid derivatives in vitro and pharmacokinetic profile in human plasma following coffee consumption. Mol. Nutr. Food Res. 2012, 56, 1413–1423.

[8] Williamson, G., Clifford, M. N., Colonic metabolites of berry polyphenols: the missing link to biological activity? Br. J. Nutr. 2010, 104, s48–s66.

[9] Gonzalez-Barrio, R., Edwards, C. A., Crozier, A., Colonic catabolism of ellagitannins, ellagic acid, and raspberry anthocyanins: in vivo and in vitro studies. Drug Metab. Dispos. 2011, 39, 1680–1688.

[10] Seto, R., Nakamura, H., Nanjo, F., Hara, Y., Preparation of epimers of tea catechins by heat treatment. Biosci. Biotechnol. Biochem. 1997, 61, 1434–1439.

[11] Gotti, R., Furlanetto, S., Lanteri, S., Olmo, S. et al., Differentiation of green tea samples by chiral CD-MEKC analysis of catechins content. Electrophoresis 2009, 30, 2922–2930.

[12] Donovan, J. L., Crespy, V., Oliveria, M., Cooper, K. A. et al., (+)-catechin is more bioavailable than (−)-catechin: relevance to the bioavailability of catechin from cocoa. Free Rad. Res. 2006, 40, 1029–1034.

[13] Ottaviani, I. J., Momma, T. Y., Heiss, C., Kwik-Uribe, C. et al., The stereochemical configuration of flavanols influences the level and metabolism of flavanols in humans and their biological activity in vivo. Free Radic. Biol. Med. 2011, 50, 237–244.

[14] Pimpao, R. C., Ventura, M. R., Ferreira, R. B., Williamson, G., Santos, C. N., Phenolic sulfates as new and highly abundant metabolites in human plasma after ingestion of a mixed berry fruit puree. Br. J. Nutr. 2015, 113, 454–463.

[15] Kay, C. D., Kroon, P. A., Cassidy, A., The bioactivity of dietary anthocyanins is likely to be mediated by their degradation products. Mol. Nutr. Food Res. 2009, 53, s92–s101.

[16] Serra, A., Macia, A., Romero, M. P., Valls, J. et al., Bioavailability of procyanidin dimers and trimers and matrix food effects in in vitro and in vivo models. Br. J. Nutr. 2010, 103, 944–952.

[17] Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377–1382.
[32] Karlsten, A., Paur, I., Bohn, S. K., Sakhi, A. K. et al., Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur. J. Nutr. 2010, 49, 345–355.

[33] Lawrence, T., Gilroy, D. W., Chronic inflammation: a failure of resolution? Int. J. Exp. Pathol. 2007, 88, 85–94.

[34] Cartwright, T., Perkins, N. D., Wilson, C., NFKB1: a suppressor of inflammation, ageing and cancer. FEBS J. 2015, doi: 10.1111/febs.13627.

[35] Zhang, J., Clark, K., Lawrence, T., Peggie, M. W., Cohen, P. An unexpected twist to the activation of IKKbeta: TAK1 primes IKKbeta for activation by autophosphorylation. Biochem. J. 2014, 461, 531–537.

[36] Clark, K., Peggie, M., Plater, L., Sorcek, R. J. et al., Novel cross-talk within the IKK family controls innate immunity. Biochem. J. 2011, 434, 93–104.

[37] Konner, A. C., Bruning, J. C., Selective insulin and leptin resistance in metabolic disorders. Cell Metab. 2012, 16, 144–155.

[38] Russo, G. L., Russo, M., Spagnuolo, C., The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia. Food Funct. 2014, 5, 2393–2401.

[39] Cullen, J. P., Morrow, D., Jin, Y., Curley, B. et al., Resveratrol, a polyphenolic phytostibene, inhibits endothelial monocyte chemotactic protein-1 synthesis and secretion. J. Vasc. Res. 2007, 44, 75–84.

[40] Lee, H. M., Lee, C. K., Lee, S. H., Roh, H. Y. et al., p38 mitogen-activated protein kinase contributes to angiotensin II-stimulated migration of rat aortic smooth muscle cells. J. Pharmacol. Sci. 2007, 105, 74–81.

[41] Hou, D. X., Kumamoto, T., Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid. Redox. Signal. 2010, 13, 691–719.

[42] Chanet, A., Milenkovic, D., Claude, S., Maier, J. A. et al., Flavanone metabolites decrease monocyte adhesion to TNF-alpha-activated endothelial cells by modulating expression of atherosclerosis-related genes. Br. J. Nutr. 2013, 110, 587–598.

[43] Claude, S., Bocy, C., Rodriguez-Mateos, A., Spencer, J. P. et al., Flavanol metabolites reduce monocyte adhesion to endothelial cells through modulation of expression of genes via p38-MAPK and p65-NF-kB pathways. Mol. Nutr. Food Res. 2014, 58, 1016–1027.

[44] Abou-Agag, L. H., Alkens, M. L., Tabengwa, E. M., Benza, R. L. et al., Polyphenolics increase t-PA and u-PA gene transcription in cultured human endothelial cells. Alcohol Clin. Exp. Res. 2001, 25, 155–162.

[45] Winterbone, M. S., Tribolo, S., Needs, P. W., Kroon, P. A., Hughes, D. A., Physiologically relevant metabolites of quercetin have no effect on adhesion molecule or chemokine expression in human vascular smooth muscle cells. Atherosclerosis 2009, 202, 431–438.

[46] Ishizawa, K., Izawa-Ishizawa, Y., Ohnishi, S., Motobayashi, Y. et al., Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells. J. Pharmacol. Sci. 2009, 109, 257–264.

[47] Ivanov, V., Ivanova, S., Kalinovsky, T., Niedzwiecki, A., Rath, M., Plant-derived micronutrients suppress monocyte adhesion to cultured human aortic endothelial cell layer by modulating its extracellular matrix composition. J. Cardiovasc. Pharmacol. 2008, 52, 55–65.

[48] Granado-Serrano, A. B., Martin, M. A., Haegeman, G., Goya, L. et al., Epicatechin induces NF-kappaB, activator protein-1 (AP-1) and nuclear transcription factor erythroid 2p45-related factor-2 (Nrf2) via phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) and extracellular regulated kinase (ERK) signalling in HepG2 cells. Br. J. Nutr. 2010, 103, 168–179.

[49] Musonda, C. A., Chipman, J. K., Quercetin inhibits hydrogen peroxide (H2O2)—induced NF-kB DNA binding activity and DNA damage in HepG2 cells. Carcinogenesis 1998, 19, 1583–1589.

[50] Granado-Serrano, A. B., Martin, M. A., Bravo, L., Goya, L., Ramos, S., Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-kappaB pathway. Nutr. Cancer 2012, 64, 588–598.

[51] Dai, X., Ding, Y., Zhang, Z., Cai, X., Li, Y., Quercetin and quercitrin protect against cytokineinduced injuries in RINm5F beta-cells via the mitochondrial pathway and NF-kappaB signaling. Int. J. Mol. Med. 2013, 31, 265–271.

[52] Dias, A. S., Porawski, M., Alonso, M., Marroni, N. et al., Quercetin decreases oxidative stress, NF-kappaB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J. Nutr. 2005, 135, 2299–2304.

[53] Comalada, M., Camuesco, D., Sierra, S., Ballester, I. et al., In vivo quercetin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through downregulation of the NF-kappaB pathway. Eur. J. Immunol. 2005, 35, 584–592.

[54] Forsythe, C. E., Phinney, S. D., Fernandez, M. L., Quann, E. E. et al., Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids 2008, 43, 65–77.

[55] Fruhbeck, G., Mendez-Gimenez, L., Fernandez-Formoso, J. A., Fernandez, S., Rodriguez, A., Regulation of adipocyte lipolysis. Nutr. Res. Rev. 2014, 27, 63–93.

[56] Abanches, M. V., Oliveira, F. C., Conceicao, L. L., Peluzio, M. D., Obesity and diabetes: the link between adipose tissue dysfunction and glucose homeostasis. Nutr. Res. Rev. 2015, 28, 121–132.

[57] Wernstedt, A., Tao, C., Morley, T. S., Wang, Q. A. et al., Pathogenic potential of adipose tissue and related inflammatory markers in subjects at increased risk of CVD. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014, 20, 103–118.

[58] Bays, H. E., Gonzalez-Campoy, J. M., Bray, G. A., Kitabchi, A. E. et al., Apoptotic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther. 2008, 6, 343–368.
[59] Wahli, W., Michalik, L., PPARs at the crossroads of lipid signaling and inflammation. *Trends Endocrinol. Metab* 2012, 23, 351–363.

[60] Margina, D., Gradinaru, D., Manda, G., Neagoe, I., Ilie, M., Membranar effects exerted in vitro by polyphenols—quercetin, epigallocatechin gallate and curcum—in HUVEC and Jurkat cells, relevant for diabetes mellitus. *Food Chem. Toxicol.* 2013, 61, 86–93.

[61] de, Luca, C., Olefsky, J. M., Stressed out about obesity and insulin resistance. *Nat. Med.* 2006, 12, 41–42.

[62] Gao, Z., Zhang, X., Zuberi, A., Hwang, D. et al., Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. *Mol. Endocrinol.* 2004, 18, 2024–2034.

[63] Zhang, C., Hwarng, G., Cooper, D. E., Grevengoed, T. J. et al., Inhibited insulin signaling in mouse hepatocytes is associated with increased phosphatidic acid but not diacylglycerol. *J. Biol. Chem.* 2015, 290, 3519–3528.

[64] Willson, T. M., Brown, P. J., Sternbach, D. D., Henke, B. R., The PPARs: from orphan receptors to drug discovery. *J. Med. Chem.* 2000, 43, 527–550.

[65] Siriwardhana, N., Kalupahana, N. S., Cekanova, M., Lemieux, M. et al., Modulation of adipose tissue inflammation by bioactive food compounds. *J. Nutr. Biochem.* 2013, 24, 613–623.

[66] Mueller, M., Lukas, B., Novak, J., Simoncini, T. et al., Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. *J. Agric. Food Chem.* 2008, 56, 11211–11630.

[67] Chuang, C. C., Martinez, K., Xie, G., Kennedy, A. et al., Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-α-mediated inflammation and insulin resistance in primary human adipocytes. *Am. J. Clin. Nutr.* 2010, 92, 1511–1521.

[68] Mochizuki, M., Kajiy, K., Terao, J., Kaji, K. et al., Effect of quercetin conjugates on vascular permeability and expression of adhesion molecules. *Biofactors* 2004, 22, 201–204.

[69] Dong, J., Zhang, X., Zhang, L., Bian, H. X. et al., Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: a mechanism including AMPKα/SIRT1. *J. Lipid Res.* 2014, 55, 363–374.

[70] Ishisaka, A., Kawabata, K., Miki, S., Shiba, Y. et al., Mitochondrial dysfunction leads to deconjugation of quercetin glucuronides in inflammatory macrophages. *PLoS ONE* 2013, 8, e80843.

[71] Kawai, Y., Nishikawa, T., Shiba, Y., Saito, S. et al., Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. *J. Biol. Chem.* 2008, 283, 9424–9434.

[72] Overman, A., Chuang, C. C., McIntosh, M., Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media. *Int. J. Obes.* 2011, 35, 1165–1172.

[73] Kawai, Y., Tanaka, H., Murota, K., Naito, M., Terao, J., (–)-Epicatechin gallate accumulates in foamy macrophages in human atherosclerotic aorta: implication in the anti-atherosclerotic actions of tea catechins. *Biochem. Biophys. Res. Commun.* 2008, 374, 527–532.

[74] Tian, C., Ye, X., Zhang, R., Long, J. et al., Green tea polyphenols reduced fat deposits in high-fat-fed rats via erk1/2-PPARgamma-adiponectin pathway. *PLoS ONE* 2013, 8, e53796.

[75] Shin, D. W., Kim, S. N., Lee, S. M., Lee, W. et al., (–)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation. *Biochem. Pharmacol.* 2009, 77, 125–133.

[76] Barth, S. W., Koch, T. C., Watzl, B., Dietrich, H. et al., Moderate effects of apple juice consumption on obesity-related markers in obese men: impact of diet-gene interaction on body fat content. *Eur. J. Nutr.* 2012, 51, 841–850.

[77] Cardona, F., Tusek, I., Tasset, I., Montilla, P. et al., Fat overload aggravates oxidative stress in patients with the metabolic syndrome. *Eur. J. Clin. Invest* 2008, 38, 510–515.

[78] Jandeleit-Dahm, K., Cooper, M. E., The role of AGEs in cardiovascular disease. *Curr. Pharm. Des.* 2008, 14, 979–986.

[79] Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001, 414, 813–820.

[80] Loh, K., Deng, H., Fukushima, A., Cai, X. et al., Reactive oxygen species enhance insulin sensitivity. *Cell Metab.* 2009, 10, 260–272.

[81] Coope, A., Torsoni, A. S., Vellosi, L., Mechanisms in endocrinology: metabolic and inflammatory pathways on the pathogenesis of type 2 diabetes. *Eur. J. Endocrinol.* 2015, doi: 10.1530/EJE-15-1065.

[82] Chao, C. L., Hou, Y. C., Chao, P. D., Weng, C. S., Ho, F. M., The antioxidant effects of quercetin metabolites on the prevention of high glucose-induced apoptosis of human umbilical vein endothelial cells. *Br. J. Nutr.* 2009, 101, 1165–1170.

[83] Choi, Y. J., Jeong, Y. J., Lee, Y. J., Kwon, H. M., Kang, Y. H., (–)Epigallocatechin gallate and quercetin enhance survival signaling in response to oxidant-induced human endothelial apoptosis. *J. Nutr.* 2005, 135, 707–713.

[84] Suri, S., Liu, X. H., Rayment, S., Hughes, D. A. et al., Quercetin and its major metabolites selectively modulate cyclic GMP-dependent relaxations and associated tolerance in pig isolated coronary artery. *Br. J. Pharmacol.* 2010, 159, 566–575.

[85] Ruijters, E. J., Weseler, A. R., Kicken, C., Haenen, G. R., Bast, A., The flavanol (–)-epicatechin and its metabolites protect against oxidative stress in primary endothelial cells via a direct antioxidant effect. *Eur. J. Pharmacol.* 2013, 715, 147–153.

[86] Fiorani, M., Guidarelli, A., Blasa, M., Azzolini, C. et al., Mitochondria accumulate large amounts of quercetin: prevention of mitochondrial damage and release upon oxidation of the extramitochondrial fraction of the flavonoid. *J. Nutr. Biochem.* 2010, 21, 397–404.

[87] Notas, G., Nifli, A. P., Kampa, M., Pelekanou, V. et al., Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells. *J. Nutr. Biochem.* 2012, 23, 656–666.
[88] Terao, J., Murota, K., Kawai, Y., Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food Funct. 2011, 2, 11–17.

[89] Kawai, Y., beta-Glucuronidase activity and mitochondrial dysfunction: the sites where flavonoid glucuronides act as anti-inflammatory agents. J. Clin. Biochem. Nutr. 2014, 54, 145–150.

[90] Menendez, C., Duenas, M., Galindo, P., Gonzalez-Manzano, S. et al., Vascular deconjugation of quercetin glucuronide: the flavonoid paradox revealed? Mol. Nutr. Food Res. 2011, 55, 1780–1790.

[91] Perez, A., Gonzalez-Manzano, S., Jimenez, R., Perez-Abud, R. et al., The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with betaglucuronidase activity. Pharmacol. Res. 2014, 89, 11–18.

[92] Lang, D. R., Racker, E., Effects of quercetin and F1 inhibitor on mitochondrial ATPase and energy-linked reactions in submitchondrial particles. Biochim. Biophys. Acta 1974, 333, 180–186.

[93] Davis, F. B., Middleton, E., Jr., Davis, P. J., Blas, S. D., Inhibition by quercetin of thyroid hormone stimulation in vitro of human red blood cell Ca\(^{2+}\)-ATPase activity. Cell Calcium 1983, 4, 71–81.

[94] Gledhill, J. R., Montgomery, M. G., Leslie, A. G., Walker, J. E., Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. USA 2007, 104, 13632–13637.

[95] Mezesova, L., Bartekova, M., Javorkova, V., Vlkovicova, J. et al., Effect of quercetin on kinetic properties of renal Na,K-ATPase in normotensive and hypertensive rats. J. Physiol. Pharmacol. 2010, 61, 593–598.

[96] Ogunbayo, O. A., Michelangeli, F., Related flavonoids cause cooperative inhibition of the sarcoplasmic reticulum Ca\(^{2+}\)-ATPase by multimode mechanisms. FEBS J. 2014, 281, 766–777.

[97] Chatterjee, S., Browning, E. A., Hong, N., DeBolt, K. et al., Membrane depolarization is the trigger for PI3K/Akt activation and leads to the generation of ROS. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H105–H114.

[98] Pi, J., Bai, Y., Zhang, Q., Wong, V. et al., Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 2007, 56, 1783–1791.

[99] Dall’asta, M., Bayle, M., Neasta, J., Scazzina, F. et al., Protection of pancreatic beta-cell function by dietary polyphenols. Phytochem. Rev. 2015, 14, 933–959.

[100] Li, C., Allen, A., Kwagh, J., Doliba, N. M. et al., Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. J. Biol. Chem. 2006, 281, 10214–10221.

[101] Cai, E. P., Lin, J. K., Epigallocatechin gallate (EGCG) and rutin suppress the glutotoxicity through activating IRS2 and AMPK signaling in rat pancreatic beta cells. J. Agric. Food Chem. 2009, 57, 9817–9827.

[102] Babu, P. V., Liu, D., Gilbert, E. R., Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J. Nutr. Biochem. 2013, 24, 1777–1789.

[103] Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., Jirawatnotai, S., Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012, 35, 2121–2127.

[104] Rouse, M., Younes, A., Egan, J. M., Resveratrol and curcumin enhance pancreatic beta-cell function by inhibiting phosphodiesterase activity. J. Endocrinol. 2014, 223, 107–117.

[105] Grossman, E., Does increased oxidative stress cause hypertension? Diabetes Care 2008, 31, S185–S189.

[106] Guo, Y., Xu, A., Wang, Y., SIRT1 in endothelial cells as a novel target for the prevention of early vascular ageing. J. Cardiovasc. Pharmacol. 2015, doi: 10.1097/FJC.0000000000000344.

[107] Feletou, M., Vanhoutte, P. M., Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br. J. Pharmacol. 1988, 93, 515–524.

[108] Chen, G., Suzuki, H., Weston, A. H., Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br. J. Pharmacol. 1988, 95, 1165–1174.

[109] Shimokawa, H., Godo, S., Diverse functions of endothelial NO synthases system: NO and EDH. J. Cardiovasc. Pharmacol. 2015, doi: 10.1097/FJC.0000000000000348.

[110] Sansone, R., Rodriguez-Mateos, A., Heuel, J., Falk, D. et al., Cocoa flavanols improve endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study. Br. J. Nutr. 2015, 114, 1246–1255.

[111] Jimenez, R., Duarte, J., Perez-Vizcaino, F., Epicatechin: endothelial function and blood pressure. J. Agric. Food Chem. 2012, 60, 8823–8830.

[112] Hooper, L., Kay, C., Abdelhamid, A., Kroon, P. A. et al., Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am. J. Clin. Nutr. 2012, 95, 740–751.

[113] Cicero, A. F., Colletti, A., Nutraceuticals and blood pressure control: results from clinical trials and meta-analyses. High Blood Press Cardiovasc. Prev. 2015, 22, 203–213.

[114] Latham, L. S., Hensen, Z. K., Minor, D. S., Chocolate—guilty pleasure or healthy supplement? J. Clin. Hypertens. 2014, 16, 101–106.

[115] Loke, W. M., Hodgson, J. M., Proudfoot, J. M., McKinley, A. J. et al., Pure dietary flavonoids quercetin and (−)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am. J. Clin. Nutr. 2008, 88, 1018–1025.

[116] Quinones, M., Margalef, M., Arola-Arnal, A., Muguerza, B. et al., The blood pressure effect and related plasma levels of flavan-3-ols in spontaneously hypertensive rats. Food Funct. 2015, 6, 3479–3489.

[117] Schnorr, O., Brossette, T., Momma, T. Y., Kleinbongard, P. et al., Cocoa flavanols lower vascular arginase activity in human endothelial cells in vitro and in erythrocytes in vivo. Arch. Biochem. Biophys. 2008, 476, 211–215.
[118] Rodriguez-Mateos, A., Toro-Funes, N., Cifuentes-Gomez, T., Cortese-Krott, M. et al., Uptake and metabolism of (−)-epicatechin in endothelial cells. Arch. Biochem. Biophys. 2014, 559, 17–23.

[119] Steffen, Y., Gruber, C., Schewe, T., Sies, H., Mono-O-methylated flavonoids and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch. Biochem. Biophys. 2008, 469, 209–219.

[120] Forstermann, U., Li, H., Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br. J. Pharmacol. 2011, 164, 213–223.

[121] Fleissner, F., Thum, T., Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid. Redox. Signal. 2011, 15, 933–948.

[122] Tribolo, S., Lodi, F., Winterbone, M. S., Saha, S. et al., Human metabolic transformation of quercetin blocks its capacity to decrease endothelial nitric oxide synthase (eNOS) expression and endothelin-1 secretion by human endothelial cells. J. Agric. Food Chem. 2013, 61, 8589–8596.

[123] Carnevale, R., Loffredo, L., Nocella, C., Bartimoccia, S. et al., Epicatechin and catechin modulate endothelial activation induced by platelets of patients with peripheral artery disease. Oxid. Med. Cell Longev. 2014, 2014, 691015.

[124] Liu, L., Xu, D. M., Cheng, Y. Y., Distinct effects of naringenin and hesperetin on nitric oxide production from endothelial cells. J. Agric. Food Chem. 2008, 56, 824–829.

[125] Shen, Y., Croft, K. D., Hodgson, J. M., Kyle, R. et al., Quercetin and its metabolites improve vessel function by inducing eNOS activity via phosphorylation of AMPK. Biochem. Pharmacol. 2012, 84, 1036–1044.

[126] Jackson, S. J., Venema, R. C., Quercetin inhibits eNOS, microtubule polymerization, and mitotic progression in bovine aortic endothelial cells. J. Nutr. 2006, 136, 1178–1184.

[127] Li, P. G., Sun, L., Han, X., Ling, S. et al., Quercetin induces rapid eNOS phosphorylation and vasodilation by an Akt-independent and PKA-dependent mechanism. Pharmacology 2012, 89, 220–228.

[128] Sanchez, M., Galisteo, M., Vera, R., Villar, I. C. et al., Quercetin downregulates NADPH oxidase, increases eNOS activity and prevent endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. 2006, 24, 75–84.

[129] Diaz-Perez, F., Radojkovic, C., Aguiler, V., Veas, C. et al., L-arginine transport and nitric oxide synthesis in human endothelial progenitor cells. J. Cardiovasc. Pharmacol. 2012, 60, 439–449.

[130] Matsuno, K., Yamada, H., Iwata, K., Jin, D. et al., Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112, 2677–2685.

[131] Gao, L., Mann, G. E., Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc. Res. 2009, 82, 9–20.

[132] Liu, S., Ma, X., Gong, M., Shi, L. et al., Glucose down-regulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic. Biol. Med. 2007, 42, 852–863.

[133] Quagliaro, L., Piccoli, L., Assaloni, R., Martinelli, L. et al., Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52, 2796–2804.

[134] Jimenez, R., Lopez-Sepulveda, R., Romero, M., Toral, M. et al., Quercetin and its metabolites inhibit the membrane NADPH oxidase activity in vascular smooth muscle cells from normotensive and spontaneously hypertensive rats. Food Funct. 2015, 6, 409–414.

[135] Brossette, T., Hundsdorfer, C., Krancke, K. D., Sies, H., Stahl, W., Direct evidence that (−)-epicatechin increases nitric oxide levels in human endothelial cells. Eur. J. Nutr. 2011, 50, 595–599.

[136] Kostyk, V. A., Potapovich, A. I., Suhan, T. O., de, L. C., Korkina, L. G., Antioxidant and signal modulation properties of plant polyphenols in controlling vascular inflammation. Eur. J. Pharmacol. 2011, 658, 248–256.

[137] Steffen, Y., Schewe, T., Sies, H., (−)-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase. Biochem. Biophys. Res. Commun. 2007, 359, 828–833.

[138] Sarafidis, P. A., Bakris, G. L., Review: Insulin and endothelin: an interplay contributing to hypertension development? J. Clin. Endocrinol. Metab. 2007, 92, 379–385.

[139] Nicholson, S. K., Tucker, G. A., Brameld, J. M., Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc. Nutr. Soc. 2008, 67, 42–47.

[140] Lodi, F., Jimenez, R., Moreno, L., Kroon, P. A. et al., Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta. Atherosclerosis 2009, 204, 34–39.

[141] Zhao, X. Y., Gu, Z. L., Effects of quercetin on production and release of endothelin and cGMP from cultured endothelial cells. Acta Pharmacol. Sinica 1996, 17, 442–444.

[142] Maranpon, F., Gravina, G. L., Scarsella, L., Festuccia, C. et al., Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis. J. Hypertens. 2013, 31, 1972–1983.

[143] Kossmann, S., Hu, H., Steven, S., Schonfelder, T. et al., Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by angiotensin II. J. Biol. Chem. 2014, 289, 27540–27550.

[144] Jekell, A., Malmqvist, K., Wallen, N. H., Mortsell, D., Kahan, W., Direct evidence that (−)-epicatechin increases nitric oxide levels in human endothelial cells. Eur. J. Nutr. 2011, 50, 595–599.

[145] Carnevale, R., Loffredo, L., Nocella, C., Bartimoccia, S. et al., Epicatechin and catechin modulate endothelial activation induced by platelets of patients with peripheral artery disease. Oxid. Med. Cell Longev. 2014, 2014, 691015.

[146] Liu, L., Xu, D. M., Cheng, Y. Y., Distinct effects of naringenin and hesperetin on nitric oxide production from endothelial cells. J. Agric. Food Chem. 2008, 56, 824–829.

[147] Shen, Y., Croft, K. D., Hodgson, J. M., Kyle, R. et al., Quercetin and its metabolites improve vessel function by inducing eNOS activity via phosphorylation of AMPK. Biochem. Pharmacol. 2012, 84, 1036–1044.

[148] Jackson, S. J., Venema, R. C., Quercetin inhibits eNOS, microtubule polymerization, and mitotic progression in bovine aortic endothelial cells. J. Nutr. 2006, 136, 1178–1184.

[149] Li, P. G., Sun, L., Han, X., Ling, S. et al., Quercetin induces rapid eNOS phosphorylation and vasodilation by an Akt-independent and PKA-dependent mechanism. Pharmacology 2012, 89, 220–228.

[150] Sanchez, M., Galisteo, M., Vera, R., Villar, I. C. et al., Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. 2006, 24, 75–84.

[151] Diaz-Perez, F., Radojkovic, C., Aguiler, V., Veas, C. et al., L-arginine transport and nitric oxide synthesis in human endothelial progenitor cells. J. Cardiovasc. Pharmacol. 2012, 60, 439–449.

[152] Matsuno, K., Yamada, H., Iwata, K., Jin, D. et al., Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112, 2677–2685.

[153] Gao, L., Mann, G. E., Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc. Res. 2009, 82, 9–20.

[154] Liu, S., Ma, X., Gong, M., Shi, L. et al., Glucose down-regulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic. Biol. Med. 2007, 42, 852–863.
[146] Chen, H. F., Liu, S. J., Chen, G., Heat shock protein 27 phosphorylation in the proliferation and apoptosis of human umbilical vein endothelial cells induced by high glucose through the phosphoinositide-3-kinase/Akt and extracellular signal-regulated kinase 1/2 pathways. *Mol. Med. Rep.* 2015, 11, 1504–1508.

[147] Yoshizumi, M., Tsuchiya, K., Suzaki, Y., Kirima, K. et al., Quercetin glucuronide prevents VSMC hypertrophy by angiotsin II via the inhibition of JNK and AP-1 signaling pathway. *Biochem. Biophys. Acta* 2010, 1852, 114, 501–506.

[148] Chae, Y. J., Kim, C. H., Ha, T. S., Hescheler, J. et al., Epigallocatechin-3-O-gallate inhibits the angiotsin II-induced adhesion molecule expression in human umbilical vein endothelial cell via inhibition of MAPK pathways. *Cell Physiol. Biochem.* 2007, 20, 859–866.

[149] Balasuriya, N., Rupasinghe, H. P., Antihypertensive properties of flavonoid-rich apple peel extract. *Food Chem.* 2012, 135, 2320–2325.

[150] Su, J. B., Vascular endothelial dysfunction and pharmacological treatment. *World J. Cardiol.* 2015, 7, 719–741.

[151] Kim, M. H., Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading pro- teases. *J. Cell Biochem.* 2003, 89, 529–538.

[152] Gonzalez-Abuin, N., Martinez-Micaelo, N., Margalef, M., Blay, M. et al., A grape seed extract increases active glucagon-like peptide-1 levels after an oral glucose load in rats. *Food Funct.* 2014, 5, 2357–2364.

[153] Ivanov, V., Roomi, M. W., Kalinovsky, T., Rath, M., Bioflavonoids effectively inhibit smooth muscle cell-mediated contraction of collagen matrix induced by angiotsin II. *J. Cardiovasc. Pharmacol.* 2005, 46, 570–576.

[154] Chen, W., Gardner, J. P., Kimura, M., Brimacombe, M. et al., Leukocyte telomere length is associated with HDL cholesterol levels: the Bogalusa heart study. *Atherosclerosis* 2009, 205, 620–625.

[155] D’Onofrio, N., Vitiello, M., Casale, R., Servillo, L. et al., Sirtuins in vascular diseases: emerging roles and thera peutic potential. *Biochim. Biophys. Acta* 2015, 1852, 1311–1322.

[156] Novelle, M. G., Wahl, D., Dieguez, C., Bernier, M., de C. R., Resveratrol supplementation: where are we now and where should we go? *Ageing Res. Rev.* 2015, 21, 1–15.

[157] Park, E. J., Pezzuto, J. M., The pharmacology of resveratrol in animals and humans. *Biochim. Biophys. Acta* 2015, 1852, 1071–1113.

[158] Li, L., Zhang, H. N., Chen, H. Z., Gao, P. et al., SIRT1 acts as a modulator of neointima formation following vascular injury in mice. *Circ. Res.* 2011, 108, 1180–1189.

[159] Chung, S., Yao, H., Cai, X., Hwang, J. W. et al., Regulation of SIRT1 in cellular functions: role of polyphenols. *Arch. Biochem. Biophys.* 2010, 501, 79–90.

[160] Richette, P., Bardin, T., Gout. *Lancet* 2010, 375, 318–328.

[161] Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W. et al., Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 2003, 425, 191–196.

[162] Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D. et al., SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. *J. Biol. Chem.* 2010, 285, 8340–8351.

[163] Liu, Z., Jiang, C., Zhang, J., Liu, B., Du, Q., Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities. *J. Diabetes* 2015, doi: 10.1111/1753-0407.12296.

[164] Thirunavukkarasu, M., Penumathsa, S. V., Koneru, S., Juhasz, B. et al., Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. *Free Radic. Biol. Med.* 2007, 43, 720–729.

[165] Penumathsa, S. V., Koneru, S., Samuel, S. M., Maulik, G. et al., Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, heme oxygenase-1, and vascular endothelial growth factor. *Free Radic. Biol. Med.* 2008, 45, 1027–1034.

[166] Takizawa, Y., Kosuge, Y., Awaji, H., Tamura, E. et al., Up-regulation of endothelial nitric oxide synthase (eNOS), silent mating type information regulation 2 homologue 1 (SIR2T1) and autophagy-related genes by repeated treatments with resveratrol in human umbilical vein endothelial cells. *Br. J. Nutr.* 2013, 110, 2150–2155.

[167] Turan, B., Tuncay, E., Vassort, G., Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. *J. Bioenerg. Biomembr.* 2012, 44, 281–296.

[168] Faghizadeh, F., Adibi, P., Hekmatdoost, A., The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. *Br. J. Nutr.* 2015, 114, 796–803.

[169] Samsami-Kor, M., Daryani, N. E., Asl, P. R., Hekmat doost, A., Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. *Arch. Med. Res.* 2015, 46, 280–285.

[170] Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B. et al., Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. *Cell Metab.* 2012, 16, 658–664.

[171] Poulsen, M. M., Fjeldborg, K., Ormstrup, M. J., Kjaer, T. N. et al., SRT1720, SRT2183, SRT1460, and resveratrol are not strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, heme oxygenase-1, and vascular endothelial growth factor. *Mol. Nutr. Food Res.* 2016, 60, 1770–1788.
[174] Geraets, L., Moonen, H. J., Brauers, K., Wouters, E. F. et al., Dietary flavones and flavonoids are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. J. Nutr. 2007, 137, 2190–2195.

[175] Kellenberger, E., Kuhn, I., Schuber, F., Muller-Steffner, H., Flavonoids as inhibitors of human CD38. Bioorg. Med. Chem. Lett. 2011, 21, 3939–3942.

[176] Chien, K. L., Chen, M. F., Hsu, H. C., Chang, W. T. et al., Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin. Chem. 2008, 54, 310–316.

[177] Remedios, C., Shah, M., Bhasker, A. G., Lakdawala, M., Hyperuricemia: a reality in the Indian obese. Obes. Surg. 2012, 22, 945–948.

[178] Tanaka, T., Kojima, T., Kawamori, T., Wang, A. et al., Inhibition of 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic acids. Carcinogenesis 1993, 14, 1321–1325.

[179] Lv, Q., Meng, X. F., He, F. F., Chen, S. et al., High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE 2013, 8, e56864.

[180] Dalbeth, N., House, M. E., Gamble, G. D., Horne, A. et al., Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann. Rheum. Dis. 2013, 72, 1868–1873.

[181] Lin, C. M., Chen, C. S., Chen, C. T., Liang, Y. C., Lin, J. K., Molecular modeling of flavonoids that inhibits xanthine oxidase. Biochem. Biophys. Res. Commun. 2002, 294, 167–172.

[182] Choi, H. K., Curhan, G., Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Brit. Med. J. 2008, 336, 309–312.

[183] Facchini, F., Chen, Y. D., Hollenbeck, C. B., Reaven, G. M., Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266, 3008–3011.

[184] Xu, C., Wan, X., Xu, L., Weng, H. et al., Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J. Hepatol. 2015, 62, 1412–1419.

[185] Harrison, R., Structure and function of xanthine oxidreductase: where are we now? Free Radic. Biol. Med. 2002, 33, 774–797.

[186] Beiler, J. M., Martin, G. J., The inhibition of xanthine oxidase by flavonoids and related compounds. J. Biol. Chem. 1951, 192, 833–834.

[187] Cos, P., Ying, L., Calomme, M., Hu, J. P. et al., Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. J Nat. Prod. 1998, 61, 71–76.

[188] Day, A. J., Bao, Y. P., Morgan, M. R. A., Williamson, G., Conjugation position of quercetin glucuronides and effect on biological activity. Free Rad. Biol. Med. 2000, 29, 1234–1243.

[189] Nagao, A., Seki, M., Kobayashi, H., Inhibition of xanthine oxidase by flavonoids. Biosci. Biotechnol. Biochem. 1999, 63, 1787–1790.

[190] Lin, S., Zhang, G., Liao, Y., Pan, J., Gong, D., Dietary flavonoids as xanthine oxidase inhibitors: structure-affinity and structure-activity relationships. J. Agric. Food Chem. 2015, 63, 7784–7794.

[191] Haidari, F., Rashidi, M. R., Esraghian, M. R., Mahboob, S. A. et al., Hypouricemic and antioxidant activities of Allium cepa Lilliaceae and quercetin in normal and hyperuricemic rats. South. Med. J. 2008, 96, 1573–1579.

[192] Mo, S. F., Zhou, F., Lv, Y. Z., Hu, Q. H. et al., Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol. Pharm. Bull. 2007, 30, 1551–1556.

[193] Shi, Y., Williamson, G., Comparison of the urinary excretion of quercetin glycosides from red onion and aglycone from dietary supplements in healthy subjects: a randomized, single-blinded, placebo-controlled, cross-over trial. Brit. J. Nutr. 2016, 115, 800–806.

[194] Shi, Y., Williamson, G., Quercetin lowers plasma uric acid in pre-hyperuricemic males: a randomized, double-blinded, placebo-controlled, cross-over trial. Brit. J. Nutr. 2016, 115, 833–841.